# SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

> **NCT07022002** · PHASE2 · RECRUITING · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 340 (estimated)

## Conditions studied

- Locally Advanced, Recurrent or Metastatic Malignancies

## Interventions

- **DRUG:** SSGJ-705
- **DRUG:** PD-1/L1 inhibitor combined with chemotherapy
- **DRUG:** SSGJ-705 combined with chemotherapy

## Key facts

- **NCT ID:** NCT07022002
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-12
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07022002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07022002, "SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07022002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*